Safety and Immunogenicity Study of an Influenza Vaccination Strategy Including an H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-18 Years Old

Conditions:   Influenza;   Influenza Immunisation Interventions:   Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine;   Biological: Influenza Virus Quadrivalent Inactivated Vaccine;   Other: Placebo Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials